2-Quinoxalineacetamide, α-cyano-3-(hexahydro-1H-azepin-1-yl)-N-[1-(4-methoxyphenyl)-2-(4-morpholinyl)ethyl]- manufacturers
|
| | 2-Quinoxalineacetamide, α-cyano-3-(hexahydro-1H-azepin-1-yl)-N-[1-(4-methoxyphenyl)-2-(4-morpholinyl)ethyl]- Basic information |
| | 2-Quinoxalineacetamide, α-cyano-3-(hexahydro-1H-azepin-1-yl)-N-[1-(4-methoxyphenyl)-2-(4-morpholinyl)ethyl]- Chemical Properties |
| Boiling point | 769.8±60.0 °C(Predicted) | | density | 1.222±0.06 g/cm3(Predicted) | | pka | 14.93±0.46(Predicted) |
| | 2-Quinoxalineacetamide, α-cyano-3-(hexahydro-1H-azepin-1-yl)-N-[1-(4-methoxyphenyl)-2-(4-morpholinyl)ethyl]- Usage And Synthesis |
| Uses | hIgG–hFc receptor-IN-1 (comp 66) is a human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein-protein interaction inhibitor, with an IC50 of 2 μM [1]. | | References | [1] Zhaolin Wang, et al. Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1253-6. DOI:10.1016/j.bmcl.2013.01.014 |
| | 2-Quinoxalineacetamide, α-cyano-3-(hexahydro-1H-azepin-1-yl)-N-[1-(4-methoxyphenyl)-2-(4-morpholinyl)ethyl]- Preparation Products And Raw materials |
|